27-11-2012 | Stefanie Andrea Erika Held, Katharina Maria Duchardt, Stefan Tenzer, Thomas Rückrich, Karin von Schwarzenberg, Anita ..., Cancer Immunology, Immunotherapy, 2012

Imatinib (IM) has been described to modulate the function of dendritic cells and T lymphocytes and to affect the expression of antigen in CML cells. In our study, we investigated the effect of the tyrosine kinase inhibitors IM and nilotinib (NI) on antigen presentation and processing by ...

more

26-11-2012 | Malgorzata Stec, Jarosław Baran, Rafał Szatanek, Bożenna Mytar, Marzena Lenart, Antoni Czupryna, Antoni Szczepanik, ..., Cancer Immunology, Immunotherapy, 2012

Monocytes exhibit direct and indirect antitumour activities and may be potentially useful for various forms of adoptive cellular immunotherapy of cancer. However, blood is a limited source of them. This study explored whether monocytes can be obtained from bone marrow haematopoietic CD34+ ...

more

26-11-2012 | Diana Barthel, Barbara Seliger, Cancer Immunology, Immunotherapy, 2012

“Tumor Immunology Meets Oncology (TIMO) VIII” from May 4 to 5, 2012, in Halle/Saale, Germany Content Type Journal Article Category Meeting report Pages 1-6 DOI 10.1007/s00262-012-1374-6 Authors Diana Barthel, Institute of Medical Immunology, Martin-Luther University ...

more

26-11-2012 | Fabricio de Carvalho, Veruska L. F. Alves, Walter M. T. Braga, Celso V. Xavier Jr., Gisele W. B. Colleoni, Cancer Immunology, Immunotherapy, 2012

The exact function of MAGE-C1/CT7 and MAGE-C2/CT10 is not yet understood in multiple myeloma (MM). However, the homologs MAGE-C1/CT7 and MAGE-C2/CT10 genes encode highly immunogeneic cancer/testis antigens (CTAs) and can be potential targets for T cell-based immunotherapy. MAGE-C1/CT7 and ...

more

26-11-2012 | Zhu Xishan, Zhou Xinna, He baoxin, Ren Jun, Cancer Immunology, Immunotherapy, 2012

Backgroud Cancer stem cells (CSCs) are proposed to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Development of specific therapies targeted at CSCs holds hope for the improvement of survival and quality of life of cancer patients, ...

more

14-11-2012 | Tomoharu Sugie, Kaoru Murata-Hirai, Masashi Iwasaki, Craig T. Morita, Wen Li, Haruki Okamura, Nagahiro Minato, Masak ..., Cancer Immunology, Immunotherapy, 2012

Human γδ T cells display potent cytotoxicity against various tumor cells pretreated with zoledronic acid (Zol). Zol has shown benefits when added to adjuvant endocrine therapy for patients with early-stage breast cancer or to standard chemotherapy for patients with multiple myeloma. Although ...

more

14-11-2012 | Kory L. Alderson, Mitchell Luangrath, Megan M. Elsenheimer, Stephen D. Gillies, Fariba Navid, Alexander L. Rakhmilev ..., Cancer Immunology, Immunotherapy, 2012

Targeted monoclonal antibodies (mAb) can be used therapeutically for tumors with identifiable antigens such as disialoganglioside GD2, expressed on neuroblastoma and melanoma tumors. Anti-GD2 mAbs (αGD2) can provide clinical benefit in patients with neuroblastoma. An important mechanism of ...

more

11-11-2012 | Zhijuan Diao, Juan Shi, Jieqing Zhu, Haiqin Yuan, Qiang Ru, Shilian Liu, Yanxin Liu, Dexian Zheng, Cancer Immunology, Immunotherapy, 2012

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a promising and novel anticancer cytokine, specifically kills numerous tumor cells by apoptosis. However, some malignancies are resistant to TRAIL treatment in clinical trials, thus limiting its therapeutic potential. In the ...

more

11-11-2012 | Daisuke Nobuoka, Toshiaki Yoshikawa, Mari Takahashi, Tatsuaki Iwama, Kazutaka Horie, Manami Shimomura, Shiro Suzuki, ..., Cancer Immunology, Immunotherapy, 2012

Antigen-specific cancer immunotherapy is a promising strategy for improving cancer treatment. Recently, many tumor-associated antigens and their epitopes recognized by cytotoxic T lymphocytes (CTLs) have been identified. However, the density of endogenously presented antigen-derived peptides ...

more

09-11-2012 | Muhammad Baghdadi, Hiroko Nagao, Hironori Yoshiyama, Hisaya Akiba, Hideo Yagita, Hirotoshi Dosaka-Akita, Masahisa Ji ..., Cancer Immunology, Immunotherapy, 2012

Cancer vaccines have been developed to instruct the endogenous immune responses to autologous tumors and to generate durable clinical responses. However, the therapeutic benefits of cancer vaccines remain insufficient due to the multiple immunosuppressive signals delivered by tumors. Thus, to ...

more